Prolia 60 mg solution for injection in pre-filled syringe
Sponsors
Herlev Hospital, Xentria Inc., Region Hovedstaden, Shandong Boan Biotechnology Co. Ltd., Shandong Boan Biotechnology Co. Ltd., Region Midtjylland
Conditions
Coronary atherosclerotic status in women with postmenopausal osteoporosisMale infertilityOsteoarthritis in the knee treated with cementless total knee arthroplastyOsteogenesis imperfectaOsteoporosisPostmenopausal osteoporosisdiabetic acute Charcot foot (Charcot neuroarthropathy)
Phase 2
NAPO - Novel Approach for Oligospermia
CompletedCTIS2023-508325-27-00
Start: 2024-04-01End: 2025-01-27Target: 60Updated: 2023-12-19
NT-NOA - Novel Treatment of some men with Non-Obstructive Azoospermia
Et klinisk interventionsforsøg
Not yet recruitingCTIS2024-512996-11-00
Target: 16Updated: 2025-08-19
A 4-way randomized double-blinded migration (RSA), bone density (DXA), and
biomarker study assessing adaptive bone changes and implant fixation and
longevity of the new Regenerex Porous Titanium Tibial Tray with different
adjuvant medical therapies.
Active, not recruitingCTIS2024-514903-33-00
Start: 2014-01-12Target: 107Updated: 2025-04-07
Phase 3
A Randomized, Double-blind, Parallel-group, Active-controlled Study to Compare the Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of MAB-22 Versus Prolia® Sourced from the European Union in Postmenopausal Women with Osteoporosis
CompletedCTIS2024-512417-41-00
End: 2025-11-11Target: 440Updated: 2024-09-30
A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmenopausal women with osteoporosis
CompletedCTIS2024-513591-18-00
Start: 2023-04-26End: 2025-06-13Target: 460Updated: 2025-03-27
Phase 4
The DENOCHARCOT trial. Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.
RecruitingCTIS2024-515365-34-00
Start: 2020-11-01Target: 114Updated: 2025-06-13
Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
CompletedCTIS2024-519705-36-00
Start: 2019-03-26End: 2025-03-21Target: 57Updated: 2025-01-23
Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.
Not yet recruitingCTIS2025-522592-29-00
Target: 60Updated: 2026-02-23